Associated Genetic Biomarkers

Overview

Gene Location [1]
4q24
Pathway
Chromatin remodeling/DNA methylation
Variant Type
Loss
Gene
TET2

TET2 Loss is present in 0.08% of AACR GENIE cases, with colon adenocarcinoma, acute myeloid leukemia, salivary gland adenoid cystic carcinoma, small cell lung carcinoma, and angioimmunoblastic T-cell lymphoma having the greatest prevalence [4].

Top Disease Cases with TET2 Loss

Significance of TET2 Loss in Diseases

Lymphoma +

Acute Myeloid Leukemia +

Malignant Central Nervous System Neoplasm +

Malignant Solid Tumor +

Acute Biphenotypic Leukemia +

Acute Leukemia Of Ambiguous Lineage +

Acute Lymphoblastic Leukemia +

Atypical Teratoid/Rhabdoid Tumor +

Extrarenal Rhabdoid Tumor +

Hepatoblastoma +

Mixed Phenotype Acute Leukemia +

Retinoblastoma +

Rhabdoid Tumor +

Rhabdoid Tumor Of The Kidney +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.

Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.

4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

5. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.